JP2018093875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018093875A5 JP2018093875A5 JP2017253096A JP2017253096A JP2018093875A5 JP 2018093875 A5 JP2018093875 A5 JP 2018093875A5 JP 2017253096 A JP2017253096 A JP 2017253096A JP 2017253096 A JP2017253096 A JP 2017253096A JP 2018093875 A5 JP2018093875 A5 JP 2018093875A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 102000054960 human MASP2 Human genes 0.000 claims 2
- 238000000099 in vitro assay Methods 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361962289P | 2013-03-15 | 2013-03-15 | |
| US61/962,289 | 2013-03-15 | ||
| US201361823964P | 2013-05-16 | 2013-05-16 | |
| US61/823,964 | 2013-05-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Division JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018093875A JP2018093875A (ja) | 2018-06-21 |
| JP2018093875A5 true JP2018093875A5 (enExample) | 2018-08-16 |
| JP6615854B2 JP6615854B2 (ja) | 2019-12-04 |
Family
ID=51538337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Withdrawn JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
| JP2017253096A Active JP6615854B2 (ja) | 2013-03-15 | 2017-12-28 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Withdrawn JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20150017162A1 (enExample) |
| EP (1) | EP2968546B1 (enExample) |
| JP (2) | JP2016514456A (enExample) |
| AU (3) | AU2014229020B2 (enExample) |
| CA (1) | CA2906096C (enExample) |
| ES (1) | ES2964340T3 (enExample) |
| NZ (2) | NZ629682A (enExample) |
| WO (1) | WO2014144542A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140363433A1 (en) * | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| EA201790946A8 (ru) * | 2014-12-01 | 2018-10-31 | Зе Скриппс Рисёрч Инститьют | Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы |
| CA3185172A1 (en) * | 2016-01-05 | 2017-07-13 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| EP3606965A4 (en) * | 2017-04-03 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MASP-1 ANTIBODY AND METHOD OF USING |
| WO2018185284A1 (en) | 2017-04-07 | 2018-10-11 | Miltenyi Biotec Gmbh | POLYPEPTIDES WITH MUTANT HUMAN IgG4 |
| SG11202100087WA (en) * | 2018-05-10 | 2021-02-25 | Mirabiologics Inc | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
| MX2021013616A (es) | 2019-05-07 | 2021-12-10 | Bayer Ag | Compuestos inhibidores de la masp y usos de estos. |
| TWI834025B (zh) | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
| WO2022096394A1 (en) | 2020-11-04 | 2022-05-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| WO2022228364A1 (zh) * | 2021-04-25 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 抗masp2抗体、其抗原结合片段及医药用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| KR100490669B1 (ko) * | 2001-08-30 | 2005-05-19 | (주)아비코아생명공학연구소 | 조류 콕시듐증을 유발하는 에이메리아 종의 포자소체 표면항원에 대한 ｓｃＦｖ 재조합 항체 |
| WO2004002417A2 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
| WO2004009664A2 (en) | 2002-07-19 | 2004-01-29 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| JP2006522122A (ja) * | 2003-03-05 | 2006-09-28 | インネクサス バイオテクノロジー インコーポレイテッド | 膜貫通抗体誘導型のアポトーシス阻害 |
| PL2374819T3 (pl) * | 2003-05-12 | 2017-09-29 | Helion Biotech Aps | Przeciwciała przeciwko MASP-2 |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20130266559A1 (en) | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| WO2007048022A2 (en) * | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
| AR056806A1 (es) * | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8679845B2 (en) | 2007-05-31 | 2014-03-25 | University Of Washington | B cells modified to reversibly induce accelerated mutagenesis of target genes |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| JP5901517B2 (ja) * | 2009-05-28 | 2016-04-13 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗原結合性タンパク質 |
| CN102781471B (zh) * | 2009-10-16 | 2016-10-12 | 奥默罗斯公司 | 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法 |
| US20130102261A1 (en) | 2010-07-01 | 2013-04-25 | Thomson Licensing | Method for calibrating a band rejection filter of a terminal and multistandard terminal with calibrated band rejection filter |
| HUP1000366A2 (en) * | 2010-07-13 | 2012-03-28 | Mta Enzimologiai Intezet | Novel proteins, their production process and use tereof |
| CA2832187C (en) * | 2011-04-08 | 2017-10-10 | Gregory A. Demopulos | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US9011860B2 (en) | 2011-05-04 | 2015-04-21 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| CA2839986A1 (en) * | 2011-06-20 | 2012-12-27 | St. Louis University | Targeting the neuromuscular junction for treatment |
| NZ781091A (en) * | 2012-04-06 | 2022-04-29 | Omeros Corp | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria |
| WO2013192240A2 (en) | 2012-06-18 | 2013-12-27 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2014
- 2014-03-14 WO PCT/US2014/028999 patent/WO2014144542A2/en not_active Ceased
- 2014-03-14 US US14/213,630 patent/US20150017162A1/en not_active Abandoned
- 2014-03-14 ES ES14764165T patent/ES2964340T3/es active Active
- 2014-03-14 EP EP14764165.8A patent/EP2968546B1/en active Active
- 2014-03-14 NZ NZ629682A patent/NZ629682A/en unknown
- 2014-03-14 AU AU2014229020A patent/AU2014229020B2/en active Active
- 2014-03-14 NZ NZ729747A patent/NZ729747A/en unknown
- 2014-03-14 JP JP2016502958A patent/JP2016514456A/ja not_active Withdrawn
- 2014-03-14 CA CA2906096A patent/CA2906096C/en active Active
-
2017
- 2017-12-15 AU AU2017276336A patent/AU2017276336A1/en not_active Abandoned
- 2017-12-28 JP JP2017253096A patent/JP6615854B2/ja active Active
-
2019
- 2019-09-05 AU AU2019226184A patent/AU2019226184B2/en active Active
-
2020
- 2020-08-04 US US16/984,287 patent/US20210079117A1/en not_active Abandoned
-
2024
- 2024-09-27 US US18/900,179 patent/US20250122309A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018093875A5 (enExample) | ||
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| JP2021503455A5 (enExample) | ||
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| IL266756A (en) | Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses | |
| JP2018108081A5 (enExample) | ||
| JP2019533719A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| HRP20170374T1 (hr) | Biološki proizvodi | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2019516394A (ja) | 新規抗ｐｄ−ｌ１抗体 | |
| JP2024056687A5 (enExample) | ||
| JP2021508707A5 (enExample) | ||
| JP2017536341A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| AU2023266270B2 (en) | Engineered anti-il-2 antibodies | |
| NZ585559A (en) | Humanized antibodies against tl1a | |
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| KR20220113353A (ko) | Ceacam5 및 cd3에 대한 이중특이적 항체 | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| JP2011506483A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| HRP20241013T1 (hr) | Protutijela za kelatirane radionuklide |